Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder

Обзор

To evaluate the safety and feasibility of collecting hematopoietic stem cells (HSC) in participants with RUNX1-FPD.

Подробное описание

Primary Objective:

\- To evaluate the safety of harvesting HSCs in participants with RUNX1 FPD

Secondary Objective

\- To evaluate the feasibility and other relevant information of collecting HSCs from participants with RUNX1 FPD

Вмешательства

• Препарат G-CSF (filgrastim or biosimilar)
  Given by IV or SC
• Процедура Apheresis
  Given by procedure
• Препарат Plerixafor
  Given by IV

Первичные конечные точки

• Safety and adverse events (AEs) [Срок оценки: Through study completion; an average of 1 year.]

Критерии участия

Критерии включения

Participants who meet all of the following criteria are eligible to be included in the study:

• Are aged ≥ 18 to 75 years

a. Once a favorable review of safety has been completed by the SMC in 3 participants aged ≥ 18 years, the study will be opened to participants aged ≥ 12 years.

• Are willing and able to provide informed consent, as appropriate (either directly or through a legally authorized representative \[LAR\]), as described in Appendix 1, Section 13.1
• Have a confirmed diagnosis of RUNX1 FPD, verified by a Clinical Laboratory Improvement Amendments (CLIA)-certified genetic sequencing report.
• Clearance by apheresis team to proceed
• Have systolic blood pressure ≤ 170 mm Hg and diastolic blood pressure ≤ 95 mmHg
• Are eligible for HSCT per institution requirements
• Have a Lansky (age < 16 years)/Karnofsky performance status of ≥ 70 (see Appendix 2, Section 13.2).
• Are willing and able to comply with protocol-defined contraceptive requirements (see Appendix 3 Section 13.3)
• Have a platelet count ≥ 50,000/μL for initiation of apheresis, assessed within 24 hours prior to the procedure, or, if < 50,000/μL are administered platelets on the day of the collection

a. If the apheresis team decides that a central venous catheter (CVC) is to be placed, platelet count should be ≥ 50,000 prior to catheter placement.

• Have hemoglobin ≥ 7.5 g/dL as assessed within 24 hours prior to the procedure

Критерии исключения

Participants who meet any of the following criteria are excluded from the study:

• Participants with cognitive impairments and/or any serious unstable pre-existing medical condition or psychiatric disorder that can interfere with safety or with obtaining informed consent or compliance with study procedures.
• Have uncontrolled bleeding
• Are using supplemental oxygen
• Have known severe splenomegaly (≥ 20 cm)
• Have a diagnosis of MDS or hematologic malignancies, as defined by WHO hematolymphoid tumor classification fifth edition (Khourey et al 2022) hematolymphoid tumor classification fifth edition (Khourey et al 2022)
• Have recent prior malignancies except resected basal cell carcinoma or treated cervical carcinoma in situ Note: Cancer treated with curative intent < 5 years previously may be allowed following approval from the study investigator. Cancer treated with curative intent > 5 years previously is allowed.
• Have any prior or current myeloproliferative or a significant coagulation or immunodeficiency disorder
• Have advanced liver disease, defined as any of the following:

• Persistent aspartate transaminase, alanine transaminase, or direct bilirubin value > 5× the upper limit of normal (ULN) at screening
• Screening prothrombin time (PT) or partial thromboplastin time (PTT) > 1.5× ULN
• Have had prior HSCT or gene therapy
• Have history of concomitant sickle cell disease
• Have been treated with an investigational drug within 30 days of screening or 5 half-lives (whichever is longer)
• Have a positive test result for HIV, hepatitis B virus (HBV), or hepatitis C virus (HCV) at screening

• Participants with positive hepatitis B core antibody (HbcAb) and/or hepatitis B-e antibody (HbeAb) are eligible provided viral load is negative by quantitative polymerase chain reaction (qPCR).
• Participants who are positive for anti-hepatitis C antibody are eligible as long as they have a negative HCV viral load by qPCR.
• Have a positive infectious disease panel at screening for human T-lymphotropic virus 1 or 2 (HTLV-1 and HTLV-2), or syphilis (rapid plasma 24 reagin \[RPR\])
• Have clinically significant and active bacterial, viral, fungal, or parasitic infection at screening
• Have a white blood cell (WBC) count < 2 × 109/L
• Have a left ventricular ejection fraction < 45%
• Have a screening estimated glomerular filtration rate < 60 mL/min/1.73 m2
• Have a diagnosis of a significant psychiatric disorder that could seriously impede the ability to participate in the study
• For women of childbearing potential: are pregnant or breastfeeding or lack adequate contraception
• Are unable to comply with the study procedures, as assessed by the investigator

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Да

Дизайн исследования

Распределение

Не применимо

Модель

Одна группа

Маскирование

Открытое

Основная цель

Фундаментальное исследование

Центры проведения

США · 1 центр

• MD Anderson Cancer Center — Houston

Идентификаторы

NCT: NCT06414889 · 2023-0799 · NCI-2024-04300

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗